(Q40432307)

20 September 2017

1 reference

title

Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy (English)

1 reference

20 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

3

R N Brogden

1 reference

20 September 2017

L R Wiseman

1

1 reference

20 September 2017

A J Wagstaff

series ordinal

2

1 reference

20 September 2017

H M Bryson

series ordinal

4

1 reference

20 September 2017

publication date

1 July 1995

1 reference

20 September 2017

1 reference

20 September 2017

volume

50

1 reference

20 September 2017

issue

1

1 reference

20 September 2017

page(s)

73-101

1 reference

Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria

20 September 2017

cites work

1 reference

12 December 2020

The pharmacokinetics of meropenem

1 reference

12 December 2020

In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia

1 reference

12 December 2020

In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.

1 reference

12 December 2020

The pharmacokinetics of meropenem in volunteers

1 reference

12 December 2020

Response of chemostat cultures of Pseudomonas aeruginosa to carbapenems and other beta-lactams.

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.

1 reference

12 December 2020

Bactericidal activity of meropenem against Pseudomonas aeruginosa

1 reference

12 December 2020

Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats

1 reference

12 December 2020

[Investigation of meropenem levels in the human bone marrow blood, bone, joint fluid and joint tissues]

1 reference

12 December 2020

Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338).

1 reference

12 December 2020

In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy

1 reference

12 December 2020

In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes

1 reference

12 December 2020

The postantibiotic effect of meropenem and imipenem on selected bacteria

1 reference

12 December 2020

L-627, a novel carbapenem: in-vitro activity against anaerobes

1 reference

12 December 2020

Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa

1 reference

12 December 2020

Extended-spectrum plasmid-mediated beta-lactamases

1 reference

12 December 2020

Effect of meropenem on the intestinal microflora

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery

1 reference

12 December 2020

Empiric monotherapy in neutropenia: a realistic goal?

1 reference

12 December 2020

Antibacterial effects of meropenem and imipenem against Haemophilus influenzae.

1 reference

12 December 2020

Meropenem: a microbiological overview

1 reference

12 December 2020

In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.

1 reference

12 December 2020

Comparative in-vitro activity of biapenem and other carbapenems against Haemophilus influenzae isolates with known resistance mechanisms to ampicillin

1 reference

12 December 2020

Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa

1 reference

12 December 2020

Pharmacokinetic and clinical studies with meropenem in the pediatric field. Pediatric Study Group of Meropenem

1 reference

12 December 2020

Pharmacokinetics of meropenem in subjects with various degrees of renal impairment

1 reference

12 December 2020

Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex.

1 reference

12 December 2020

Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.

1 reference

12 December 2020

Susceptibility of anaerobic bacteria to meropenem

1 reference

12 December 2020

Concentration of meropenem in serum and in bronchial secretions in patients undergoing fibreoptic bronchoscopy.

1 reference

12 December 2020

Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group

1 reference

12 December 2020

Antibacterial effect of meropenem and imipenem on Proteus mirabilis

1 reference

12 December 2020

Therapeutic activity of meropenem in experimental infections

1 reference

12 December 2020

Nosocomial outbreak of meropenem resistant Pseudomonas aeruginosa infections in a cancer centre

1 reference

12 December 2020

The growth-inhibitory properties of meropenem against anaerobes of clinical importance

1 reference

12 December 2020

Prevention of drug access to bacterial targets: permeability barriers and active efflux

1 reference

12 December 2020

Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group

1 reference

12 December 2020

Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy

1 reference

12 December 2020

Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic

1 reference

12 December 2020

Mechanisms of resistance to beta-lactam antibiotics

1 reference

12 December 2020

A study of the penetration of meropenem into bile using endoscopic retrograde cholangiography

1 reference

12 December 2020

In vitro activity of L-627, a new carbapenem

1 reference

12 December 2020

Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.

1 reference

12 December 2020

Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges

1 reference

12 December 2020

Permeability of the outer membrane of Moraxella catarrhalis for beta-lactam antibiotics

1 reference

12 December 2020

Comparative in-vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance.

1 reference

12 December 2020

Meropenem treatment of post-traumatic meningitis due to Pseudomonas aeruginosa

1 reference

12 December 2020

Role of OmpD2 and chromosomal β-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa

1 reference

12 December 2020

In vitro activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases

1 reference

12 December 2020

Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections

1 reference

12 December 2020

In-vivo and in-vitro study of the postantibiotic effect of meropenem.

1 reference

12 December 2020

Effect of media composition on the susceptibility of Xanthomonas mahophilia to β-lactam antibiotics

1 reference

12 December 2020

Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem

1 reference

12 December 2020

Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases.

1 reference

12 December 2020

Pharmacokinetics of meropenem in subjects with renal insufficiency

1 reference

12 December 2020

Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem

1 reference

12 December 2020

Susceptibility to beta-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 beta-lactamases

1 reference

12 December 2020

Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem

1 reference

12 December 2020

Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.

1 reference

12 December 2020

In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338.

1 reference

12 December 2020

In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I

1 reference

12 December 2020

In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp

1 reference

12 December 2020

A Multicenter Comparative Study of Meropenem and Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections in Hospitalized Patients

1 reference

12 December 2020

Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants

1 reference

12 December 2020

Antibacterial activity of the new carbapenem meropenem (SM-7338) against clinical isolates

1 reference

12 December 2020

Penicillin-binding protein (PBP) 2 and the post-antibiotic effect of carbapenems

1 reference

12 December 2020

Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment

1 reference

12 December 2020

Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics

1 reference

12 December 2020

A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.

1 reference

12 December 2020

Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.

1 reference

12 December 2020

Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex

1 reference

12 December 2020

Effect of penicillin G on Staphylococcus aureus phagocytosed by human monocytes.

1 reference

12 December 2020

Bactericidal activity of meropenem and interactions with other antibiotics.

1 reference

12 December 2020

Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium

1 reference

12 December 2020

Penetration of meropenem into heart valve tissue

1 reference

12 December 2020

Postantibiotic effect of meropenem on members of the family Enterobacteriaceae determined by five methods

1 reference

12 December 2020

Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins

1 reference

12 December 2020

Activity of a new carbapenem antibiotic, meropenem, against Haemophilus influenzae strains with beta-lactamase- and non-enzyme-mediated resistance to ampicillin

1 reference

12 December 2020

Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin

1 reference

12 December 2020

Carbapenems in paediatrics

1 reference

12 December 2020

Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial

1 reference

12 December 2020

Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes

1 reference

12 December 2020

Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.

1 reference

12 December 2020

Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms

1 reference

12 December 2020

Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom.

1 reference

12 December 2020

The disposition and metabolic fate of 14C-meropenem in man.

1 reference

12 December 2020

Activity of meropenem, against gram-positive bacteria.

1 reference

12 December 2020

Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men

1 reference

12 December 2020

Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group

1 reference

12 December 2020

Interaction of meropenem with humoral and phagocytic defences

1 reference

12 December 2020

Affinities of SM-7338 for penicillin-binding proteins and its release from these proteins in Staphylococcus aureus

1 reference

12 December 2020

Imipenem/cilastatin treatment of bacterial meningitis in children

1 reference

12 December 2020

Comparative stability of meropenem against beta-lactamases from Bacteroides spp

1 reference

12 December 2020

Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.

1 reference

12 December 2020

Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion

1 reference

12 December 2020

Heterogeneity of beta-lactamase production in Pseudomonas maltophilia, a nosocomial pathogen.

1 reference

12 December 2020

In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates

1 reference

12 December 2020

Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.

1 reference

12 December 2020

Efficacy of meropenem in experimental meningitis.

1 reference

12 December 2020

High-dose meropenem in meningitis due to Pseudomonas aeruginosa

1 reference

12 December 2020

In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338.

1 reference

12 December 2020

Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone

1 reference

12 December 2020

Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.

1 reference

12 December 2020

Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa

1 reference

12 December 2020

Stability of SM-7338, a new carbapenem in mediums recommended for the susceptibility testing of anaerobic bacteria and gonococci

1 reference

12 December 2020

Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen

1 reference

12 December 2020

Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease

1 reference

12 December 2020

Comparative in vitro activity of SM7338, a new carbapenem antimicrobial agent

1 reference

12 December 2020

Meropenem pharmacokinetics and penetration into an inflammatory exudate

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.

1 reference

12 December 2020

Comparative activity of meropenem (SM-7338) against major respiratory pathogens and amikacin-resistant nosocomial isolates

1 reference

12 December 2020

Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I

1 reference

12 December 2020

Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group

1 reference

12 December 2020

In-vitro activity of meropenem against clinical isolates obtained in Canada

1 reference

12 December 2020

In-vitro antimicrobial susceptibility of Rhodococcus equi

1 reference

12 December 2020

Multicenter in vitro evaluation of SM-7338, a new carbapenem

1 reference

12 December 2020

The antibacterial activity of meropenem in combination with gentamicin or vancomycin.

1 reference

12 December 2020

Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins

1 reference

12 December 2020

Comparison of methodologies used in assessing the postantibiotic effect

1 reference

12 December 2020

Activity of meropenem against antibiotic-resistant or infrequently encountered gram-negative bacilli

1 reference

12 December 2020

A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min

1 reference

12 December 2020

Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males

1 reference

12 December 2020

In vitro activity of L-627 against anaerobic bacteria

1 reference

12 December 2020

Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.

1 reference

12 December 2020

Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa

1 reference

12 December 2020

In vitro activity of a catechol-substituted cephalosporin, GR69153.

1 reference

12 December 2020

The entry of meropenem into human macrophages and its immunomodulating activity

1 reference

12 December 2020

Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.

1 reference

12 December 2020

The pharmacokinetics of meropenem in infants and children: a population analysis

1 reference

12 December 2020

Meropenem: evidence of lack of proconvulsive tendency in mice

1 reference

12 December 2020

In-vitro studies of meropenem

1 reference

12 December 2020

A comparison of the in vitro postantibiotic effect of meropenem and imipenem versus selected enterobacteriaceae and other pathogens

1 reference

12 December 2020

Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

1 reference

12 December 2020

Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin

1 reference

12 December 2020

In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin.

1 reference

12 December 2020

Diffusion of meropenem and imipenem through the outer membrane of Escherichia coli K-12 and correlation with their antibacterial activities

1 reference

12 December 2020

In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide.

1 reference

12 December 2020

Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy

1 reference

12 December 2020

10.2165/00003495-199550010-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1030020911

0 references

1 reference